Fundraising Fox

Kytopen

Cambridge, US · Founded 2017 · Delaware corporation · 8 known investors

Kytopen develops non-viral gene delivery technology called Flowfect that combines fluid flow with electric fields to deliver payloads such as mRNA, DNA, and CRISPR Cas9 RNP into cells for high-throughput transfection. Its platforms serve cell therapy researchers and developers, supporting drug discovery, process optimization, and scaling from small-volume experiments to manufacturing.

BiotechDeep TechHardware

Founders & leadership

Kytopen was founded in 2017 by Cullen Buie and Paulo Garcia.

CBCullen Buie
Cullen BuieCo-founder
PGPaulo Garcia
Paulo GarciaCo-founder
MC
Michael ChiuExecutive
JV
Julio VegaMr. Vega is the Secretary of the Issuer.

Board

PM
Paxton MajorBoard director
ADAnn DeWitt
Ann DeWittinBoard directorGeneral Partner at The Engine Ventures
PW
Paul WottonBoard director

Investors · 8

Bantam GroupWestwood
Horizons VenturesHong Kong · $1M – $110M
MassVenturesWaltham · $250K – $500K
Selvedge VentureLondon
TBD AngelsNew York
Telegraph Hill PartnersSan Francisco · $2M – $8M
The Engine VenturesCambridge
Northpond VenturesreportedBethesda · $100K – $5M

Funding

SEC filings, press & company announcements

$52.7M disclosed across 5 of 6 rounds · 2019–2026

▶$7.1MraisedFeb 2025 · 13 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Cullen BuieDirector
  • Julio VegaExecutive Officer
  • Michael ChiuDirector, Executive Officer
  • Paul WottonDirector
  • Paxton MajorDirector
Offering amount
$15M
Amount sold
$7.1M
First sale
Feb 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5.7MraisedFeb 2024 · 22 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Paxton MajorDirector
  • Michael ChiuDirector, Executive Officer
  • Bethany GrantExecutive Officer
  • Edward FreedmanDirector
  • Cullen BuieDirector
  • Paul WottonDirector
Offering amount
$8M
Amount sold
$5.7M
First sale
Jan 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$32.5MraisedOct 2021 · 18 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Adam WieschhausDirector
  • Paulo GarciaExecutive Officer, Director, Promoter
  • Theresa TribbleDirector
  • Cullen BuieDirector
Offering amount
$32.5M
Amount sold
$32.5M
First sale
Sep 2021
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3.1MraisedNov 2020 · 11 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Ann DeWittDirector
  • Paulo GarciaExecutive Officer, Director, Promoter
  • Cullen BuieDirector
Offering amount
$4M
Amount sold
$3.1M
First sale
Oct 2020
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4.3MraisedMay 2019 · 9 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Paulo GarciaExecutive Officer, Director, Promoter
  • Julio VegaExecutive Officer
  • Cullen BuieDirector
  • Ann DeWittDirector
Offering amount
$4.3M
Amount sold
$4.3M
First sale
May 2019
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Non-dilutive funding · 3 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase I2021$300K
National Science FoundationPhase II2019$948.2K
National Science FoundationPhase I2018$225K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

Kytopen Raises Series B to Scale Cell Therapy Manufacturing Platform - Cambridge Todaynationaltoday.com · Apr 2026Kytopen Corp. Raises Series B Financing Led by Telegraph Hill Partners | citybizcitybiz.co · Apr 2026Kytopen Expands Commercialization Efforts and Board of Directors Following Series B Investment Led by Telegraph Hill Partnersprnewswire.com · Apr 2026Kytopen Closes Series B Fundingfinsmes.com · Apr 2026Kytopen Raises $30M in Series A Funding, Led by Northpond Ventures, to Transform Non-Viral Delivery via the Flowfect Platform - Kytopenkytopen.com · Sep 2021Technology Startup Kytopen Raises $3.6 Million Seed Round - BioSpacebiospace.com · May 2019

Frequently asked questions

What does Kytopen do?
Kytopen develops non-viral gene delivery technology called Flowfect that combines fluid flow with electric fields to deliver payloads such as mRNA, DNA, and CRISPR Cas9 RNP into cells for high-throughput transfection. Its platforms serve cell therapy researchers and developers, supporting drug discovery, process optimization, and scaling from small-volume experiments to manufacturing.
Who founded Kytopen?
Kytopen was founded by Cullen Buie, Paulo Garcia in 2017.
Who are Kytopen's investors?
Kytopen's investors include Bantam Group, Horizons Ventures, MassVentures, Selvedge Venture, TBD Angels, Telegraph Hill Partners, The Engine Ventures, Northpond Ventures.
How much funding has Kytopen raised?
Kytopen has disclosed $52.7M raised across 5 of its 6 known rounds.
Where is Kytopen headquartered?
Kytopen is headquartered in Cambridge, US.